BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Gen9 today announced the launch of a powerful DNA library platform that allows users to rapidly design variants and order synthetic DNA libraries. The new platform will be unveiled at SynBioBeta San Francisco, taking place November 4-6 at the Mission Bay Conference Center in San Francisco, CA.
The platform, available within Gen9’s online design and ordering portal, is powered by Benchling, a leading developer of cloud-based tools for life science. The tool enables the design of hundreds to thousands of individual DNA variants. In just minutes, scientists can easily engineer DNA variations with precisely the sequence content desired. The ability to rapidly design arrayed libraries will accelerate discoveries across many applications, such as the identification of improved antibody therapeutics or the development of novel and more effective enzymes for detergents, food processing, or biofuels.
“This new platform is the next step in providing our customers design and order capabilities that scale with their increased adoption of powerful synthetic biology techniques,” said Kevin Munnelly, President and CEO of Gen9. “By combining high-throughput DNA design and manufacture, we are making it easier than ever to explore more sequence space using synthetic genes of unmatched quality and value. This will enable scientists to think bigger and take on more aggressive projects that might not have otherwise been possible.”
The new arrayed library tool further enhances the capabilities of Gen9’s web-based portal. The portal enables the optimization of large numbers of synthetic DNA constructs in real-time. Scientists can store, access, and edit sequence information using the Benchling DNA editor, a best-in-class tool that is already being used extensively in the life science industry.
“We are excited to partner with Gen9 on this cutting-edge design platform,” said Sajith Wickramasekara, Chief Executive Officer of Benchling. “Providing scientists with tools to speed their research is at the core of what we do, and these new design capabilities will fuel even greater innovation in the field of synthetic biology.”
Gen9 will unveil the new platform at SynBioBeta San Francisco during their hosted workshop on Thursday, November 5 at 2:40 p.m. PST in the Leach Conference Room 213. The hands-on workshop titled, “New Online Tools for High Throughput DNA Design,” will explore the new enhancements to the company’s online design and optimization portal.
For more information on the new platform, please visit www.gen9bio.com/arrayed-design.
About Gen9
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.
About Benchling
Benchling is a venture-backed company based in San Francisco that aims to increase the rate of scientific output with its cloud-based platform that allows researchers to design and run experiments, analyze data, and share results. Benchling believes an R&D organization should have all institutional knowledge at its fingertips, and that making collaboration seamless will allow science to move faster. The Benchling Research Platform is used by scientists at more than 1,000 institutions around the world. Benchling was launched in 2013 by a team of software engineers with experience in molecular and computational biology whose mission is to help scientists work together.
